Patents Assigned to International Aids Vaccine Initiative
-
Patent number: 10836811Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: September 12, 2017Date of Patent: November 17, 2020Assignees: Theraclone Sciences, Inc., The Scripps Research Institute, International AIDS Vaccine InitiativeInventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Majorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
-
Patent number: 10792357Abstract: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.Type: GrantFiled: March 4, 2019Date of Patent: October 6, 2020Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Maoli Yuan, Xinsheng Zhang, Aaron Wilson, Angela Grazia Lombardo, Eddy Sayeed, Josephine Helena Cox, Takashi Hironaka, Makoto Inoue, Hiroto Hara
-
Patent number: 10736953Abstract: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity.Type: GrantFiled: January 2, 2019Date of Patent: August 11, 2020Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Tom Jin, Eric I-Fu Tsao
-
Patent number: 10544430Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: January 27, 2017Date of Patent: January 28, 2020Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Maoli Yuan, Kevin Wright, Christy Jurgens
-
Patent number: 10428122Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: June 16, 2017Date of Patent: October 1, 2019Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
-
Patent number: 10421789Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.Type: GrantFiled: March 4, 2019Date of Patent: September 24, 2019Assignees: University of Washington, Center for Commercialization, The Scripps Research Institute, International AIDS Vaccine InitiativeInventors: Po-Ssu Huang, Joseph Graham Jardine, Sergey V. Menis, William Ray Schief, Neil P. King
-
Patent number: 10407493Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: February 14, 2019Date of Patent: September 10, 2019Assignees: THERACLONE SCIENCES, INC., INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTEInventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
-
Patent number: 10279027Abstract: The present relation relates to a transgenic Vero cell line expressing CD4 and CCR5. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: April 6, 2017Date of Patent: May 7, 2019Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Wayne C. Koff
-
Patent number: 10266574Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: June 24, 2014Date of Patent: April 23, 2019Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Ravi Anantha, Nathalie Cadieux, Thomas G. Evans, Michele Stone, Barry Walker
-
Patent number: 10239934Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: March 12, 2018Date of Patent: March 26, 2019Assignees: Theraclone Sciences, Inc., International AIDS Vaccine Initiative, The Scripps Research InstituteInventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
-
Patent number: 10221217Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.Type: GrantFiled: December 22, 2015Date of Patent: March 5, 2019Assignees: University of Washington, Center for Commercialization, The Scripps Research Institute, International AIDS Vaccine InitiativeInventors: Po-Ssu Huang, Joseph Graham Jardine, Sergey V. Menis, William Ray Schief, Neil P. King
-
Patent number: 10220087Abstract: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.Type: GrantFiled: April 27, 2017Date of Patent: March 5, 2019Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Maoli Yuan, Xinsheng Zhang, Aaron Wilson, Angela Grazia Lombardo, Eddy Sayeed, Josephine Helena Cox, Takashi Hironaka, Makoto Inoue, Hiroto Hara
-
Patent number: 10202424Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: July 31, 2017Date of Patent: February 12, 2019Assignee: International AIDS Vaccine InitiativeInventors: Christopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
-
Patent number: 10174292Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: March 21, 2016Date of Patent: January 8, 2019Assignees: International AIDS Vaccine Initiative, The Scripps Research InstituteInventors: Viktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
-
Patent number: 10093720Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.Type: GrantFiled: June 5, 2015Date of Patent: October 9, 2018Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITYInventors: Dennis R. Burton, Marit J. van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok
-
Patent number: 10087239Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: May 12, 2016Date of Patent: October 2, 2018Assignees: THERACLONE SCIENCES, INC., THE SCRIPPS RESEARCH INSTITUTE, INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Majorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
-
Patent number: 10081796Abstract: The present invention relates to novel canine distemper virus (CDV) neutralization-resistant mutants, methods for making the same and uses for vaccine production.Type: GrantFiled: January 12, 2016Date of Patent: September 25, 2018Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Xinsheng Zhang, Olivia Wallace, Arban Domi, Christopher Parks
-
Patent number: 10058604Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: October 7, 2014Date of Patent: August 28, 2018Assignees: International AIDS Vaccine Initiative, The Scripps Research InstituteInventors: Richard Wyatt, Andrew Ward, Karen Tran, Shailendra Kumar, Jidnyasa Ingale, Javier Guenaga, Yu Feng, Viktoriya Dubrovskaya, Natalia de Val Alda
-
Patent number: 9944935Abstract: The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.Type: GrantFiled: April 20, 2016Date of Patent: April 17, 2018Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Kevin J. Wright, Maoli Yuan, Christy K. Jurgens, Xinsheng Zhang, Arban Domi, Simon Hoffenberg, Maria J. Chiuchiolo, Svetlana Rabinovich, Aaron J. Wilson, Ivo C. Lorenz
-
Patent number: 9931394Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: March 21, 2016Date of Patent: April 3, 2018Assignees: International AIDS Vaccine Initiative, The Scripps Research InstituteInventors: Shailendra Kumar Sharma, Richard Wyatt